Addendum: MCC950 closes the active conformation of NLRP3 to an inactive state - PubMed

Published Erratum

Addendum: MCC950 closes the active conformation of NLRP3 to an inactive state

Ana Tapia-Abellán et al. Nat Chem Biol. 2021 Mar.

Abstract

An Addendum to this paper has been published: https://doi.org/10.1038/s41589-021-00741-6.

Erratum for

• MCC950 closes the active conformation of NLRP3 to an inactive state.

  Tapia-Abellán A, Angosto-Bazarra D, Martínez-Banaclocha H, de Torre-Minguela C, Cerón-Carrasco JP, Pérez-Sánchez H, Arostegui JI, Pelegrin P. Tapia-Abellán A, et al. Nat Chem Biol. 2019 Jun;15(6):560-564. doi: 10.1038/s41589-019-0278-6. Epub 2019 May 13. Nat Chem Biol. 2019. PMID: 31086329 Free PMC article.

Similar articles

• Addendum: Cryptic phosphorylation in nucleoside natural product biosynthesis.

  Draelos MM, Thanapipatsiri A, Sucipto H, Yokoyama K. Draelos MM, et al. Nat Chem Biol. 2021 Oct;17(10):1111-1112. doi: 10.1038/s41589-021-00867-7. Nat Chem Biol. 2021. PMID: 34381204 Free PMC article.

• Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.

  Niedhammer I, Milner A, Witt K, Klingelschmidt J, Khireddine-Medouni I, Alexopoulos EC, Toivanen S, Chastang JF, LaMontagne AD. Niedhammer I, et al. Scand J Work Environ Health. 2018 Jan 1;44(1):108-110. doi: 10.5271/sjweh.3698. Epub 2017 Dec 8. Scand J Work Environ Health. 2018. PMID: 29218357

• A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation.

  Zhang C, Zhu X, Li L, Ma T, Shi M, Yang Y, Fan Q. Zhang C, et al. Diabetes Metab Syndr Obes. 2019 Aug 2;12:1297-1309. doi: 10.2147/DMSO.S199802. eCollection 2019. Diabetes Metab Syndr Obes. 2019. PMID: 31447572 Free PMC article.

• MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.

  Bakhshi S, Shamsi S. Bakhshi S, et al. Int Immunopharmacol. 2022 May;106:108595. doi: 10.1016/j.intimp.2022.108595. Epub 2022 Feb 3. Int Immunopharmacol. 2022. PMID: 35124417 Review.

• Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.

  Wu D, Chen Y, Sun Y, Gao Q, Li H, Yang Z, Wang Y, Jiang X, Yu B. Wu D, et al. Inflammation. 2020 Feb;43(1):17-23. doi: 10.1007/s10753-019-01098-8. Inflammation. 2020. PMID: 31646445 Review.

Cited by

• Pyroptosis regulation by Salmonella effectors.

  Meng Y, Zhang Q, Xu M, Ding K, Yu Z, Li J. Meng Y, et al. Front Immunol. 2024 Oct 23;15:1464858. doi: 10.3389/fimmu.2024.1464858. eCollection 2024. Front Immunol. 2024. PMID: 39507539 Free PMC article. Review.

• In Silico Structural and Functional Analyses of NLRP3 Inflammasomes to Provide Insights for Treating Neurodegenerative Diseases.

  Ghazi BK, Bangash MH, Razzaq AA, Kiyani M, Girmay S, Chaudhary WR, Zahid U, Hussain U, Mujahid H, Parvaiz U, Buzdar IA, Nawaz S, Elsadek MF. Ghazi BK, et al. Biomed Res Int. 2023 Jan 23;2023:9819005. doi: 10.1155/2023/9819005. eCollection 2023. Biomed Res Int. 2023. PMID: 36726838 Free PMC article. Retracted.

• MCC950 improves lipopolysaccharide‑induced systemic inflammation in mice by relieving pyroptosis in blood neutrophils.

  Miao R, Huang J. Miao R, et al. Exp Ther Med. 2023 Jul 13;26(3):417. doi: 10.3892/etm.2023.12117. eCollection 2023 Sep. Exp Ther Med. 2023. PMID: 37602308 Free PMC article.

Publication types

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • scite Smart Citations